Eric YU
Partner, Head of Healthcare @ Matrix Partners China
Eric YU is a Series A investor at Matrix Partners China focused on Biotechnology and Pharmaceutical. Eric YU is based out of Huangpu District, Shanghai and is the Partner, Head of Healthcare of Matrix Partners China. Eric previously worked at Fidelity Growth Partners Asia as a VP. Eric YU attended the The Tuck School of Business at Dartmouth.
- Total investments:
- 8
- Last investment:
- Lead investor:
- 38%
Last updated:
For AI agents: llms.txt
Industries Eric YU invests in
Stages Eric YU invests in
Countries Eric YU invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 3 (38%)
- Pharmaceutical 3 (38%)
- Health Care 2 (25%)
- Manufacturing 2 (25%)
- Medical Device 2 (25%)
Stage
- Series A 3 (38%)
- Series B 3 (38%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Ucello Therapeutics is engaged in development of allogeneic cell therapies using its proprietary CAR-T cell technology platform CBT-X20. | $21.2M / Series A / Jun 02, 2023 | ||
| Ucello Therapeutics is engaged in development of allogeneic cell therapies using its proprietary CAR-T cell technology platform CBT-X20. | $25M / Series A / Feb 10, 2022 | ||
| Triastek develops 3D printed medicines and the production facilities to manufacture them and has already filed patent applications for its technology. | Series B / Nov 23, 2021 | ||
| Scivita Medical is a high-tech enterprise engaged in the field of optical diagnosis and treatment, multidimensional images development, high-performance materials research and precision manufacturing with minimally invasive medical treatment. Scivita Medical's product covers both flexible endoscopy and rigid endoscopy, and has uniqueadvantages in the research and commercialization of all cutting-edge technologies in the field of medical endoscopes. It has ultra-high-definition visualization technology (such as 4K UHD visualization), 3D visualization technology, special light visualization technology (such as fluorescence visualization), ultra-fine endoscopic visualization technology, single-use technology, etc. | $61.9M / Series B / Aug 05, 2021 | ||
| Triastek develops 3D printed medicines and the production facilities to manufacture them and has already filed patent applications for its technology. | $51M / Series B / Jun 24, 2021 | ||
| Scivita Medical is a high-tech enterprise engaged in the field of optical diagnosis and treatment, multidimensional images development, high-performance materials research and precision manufacturing with minimally invasive medical treatment. Scivita Medical's product covers both flexible endoscopy and rigid endoscopy, and has uniqueadvantages in the research and commercialization of all cutting-edge technologies in the field of medical endoscopes. It has ultra-high-definition visualization technology (such as 4K UHD visualization), 3D visualization technology, special light visualization technology (such as fluorescence visualization), ultra-fine endoscopic visualization technology, single-use technology, etc. | $61.7M / Series A / Apr 26, 2021 | ||
| OnQuality Pharmaceuticals offers trials to assess the safety and efficacy of a targeted supportive care agent that addresses the specific side effects of vascular endothelial growth factor receptor (VEGFR) inhibitors among cancer patients. | $20M / Series A / Mar 31, 2021 | ||
| 23Mofang provides genetic testing services for Chinese people and conducts life data analysis business. The company relies on the Internet + genetic testing to build a large database of life, with the mission of "data life, benefit everyone", and build a trustworthy technology enterprise. | $15.7M / Series B / Mar 05, 2018 |
Co-Investors
About Matrix Partners China
Matrix Partners China builds long-term relationships with entrepreneurs and helps them build significant, industry-leading companies. Since its inception in 1977, Matrix Partners China has made hundreds of investments and played an active role in the development of many successful businesses, 50 of which went on to IPO, and 75 of which have gone on to profitable M&A events. The firm consistently ranks in the top venture firms in terms of returns to its investors. Matrix Partners China combines local knowledge with global experience and vision. Its team consists of both former entrepreneurs and experienced investors. Its past successes include Focus Media, Eachnet, and Baidu, among others. The company invests across multiple sectors and stages.
Matrix Partners China Contacts
| Name | Phone | Socials | |
|---|---|---|---|
David Zhang
Managing Partner / Co Founder
|
|||
|
Eric YU
Partner, Head of Healthcare
|
|||
Guoxiong Cao
Partner (RMB Funds)
|
|||
Kevin Xiong
Partner
|
|||
Mi Zhou
Director
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Eric YU invest in?
Eric YU invests primarily in Biotechnology, Pharmaceutical and Health Care startups, most often at Series A and Series B stage. Most of the 8 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Eric YU?
Public channels for Eric YU include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Eric YU last invest?
The most recent investment recorded for Eric YU closed in Jun 2023. Shizune tracks 8 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
